Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( BSPED ) and the Association of British Clinical Diabetologists ( ABCD )
Diabetic Medicine · 2026-07 · 43 (7)
DOI: 10.1111/dme.70329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 29.04.2026. Verfasst von Renuka P Dias und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Diabetes and Endocrinology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Diabetes Mellitus, Type 1, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK.
Methods
To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of Paediatric Endocrinology and Diabetes (BSPED) Type 1 diabetes Special Interest Group (SIG) and the Association of British Clinical Diabetologists (ABCD) assembled a group to review the clinical trial data and develop expert consensus guidelines on the approach to teplizumab infusions.
Conclusion
Here, we present recommendations on all aspects of teplizumab administration with evidence base where available. We highlight the safety considerations in individual's selection, screening, monitoring and treatment of potential common side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Diabetes and Endocrinology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
- Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Department of Paediatrics, University of Cambridge, Cambridge, UK.
- Department of Paediatric Endocrinology and Diabetes, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Department of Paediatric Diabetes and Endocrinology, The Royal London Children's Hospital, Barts Health NHS Trust, London, UK.
- Department of Paediatrics, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
ORCID-Profile: Renuka P Dias, Parth Narendran
Zitieren
APA
Dias, R. P., Marcovecchio, M. L., Willemsen, R. H., Campbell, F., Ashour, A., Newland-Jones, P., Cooper, J., Narendran, P., & Wright, N. P. (2026). Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( BSPED ) and the Association of British Clinical Diabetologists ( ABCD ). Diabetic Medicine, 43(7). https://doi.org/10.1111/dme.70329
Vancouver
Dias RP, Marcovecchio ML, Willemsen RH, Campbell F, Ashour A, Newland-Jones P, et al. Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( BSPED ) and the Association of British Clinical Diabetologists ( ABCD ). Diabetic Medicine. 2026;43(7). doi:10.1111/dme.70329
BibTeX
@article{Dias2026,
author = {Dias, Renuka P and Marcovecchio, M Loredana and Willemsen, Ruben H and Campbell, Fiona and Ashour, Ahmad and Newland-Jones, Philip and Cooper, Jennifer and Narendran, Parth and Wright, Neil P},
title = {Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( BSPED ) and the Association of British Clinical Diabetologists ( ABCD )},
journal = {Diabetic Medicine},
year = {2026},
volume = {43},
number = {7},
doi = {10.1111/dme.70329}
}
EUVIMED